Insider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) CFO Acquires $10,809.15 in Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) CFO Kelly Gold acquired 6,551 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $1.65 per share, with a total value of $10,809.15. Following the completion of the transaction, the chief financial officer directly owned 74,428 shares of the company’s stock, valued at $122,806.20. This trade represents a 9.65% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

CAMP4 Therapeutics Trading Down 5.8%

CAMP4 Therapeutics stock opened at $4.24 on Friday. The firm’s 50 day simple moving average is $4.02 and its 200 day simple moving average is $4.30. The firm has a market capitalization of $220.18 million, a PE ratio of -1.80 and a beta of 0.22. CAMP4 Therapeutics Corporation has a 1-year low of $1.32 and a 1-year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%.The firm had revenue of $1.29 million during the quarter. Research analysts forecast that CAMP4 Therapeutics Corporation will post -0.84 earnings per share for the current year.

Institutional Trading of CAMP4 Therapeutics

Hedge funds have recently made changes to their positions in the stock. Bridgeway Capital Management LLC purchased a new position in CAMP4 Therapeutics in the second quarter worth $36,000. China Universal Asset Management Co. Ltd. purchased a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $61,000. Jefferies Financial Group Inc. bought a new stake in CAMP4 Therapeutics during the fourth quarter worth about $70,000. Bank of America Corp DE bought a new stake in CAMP4 Therapeutics during the fourth quarter worth about $86,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of CAMP4 Therapeutics in the 4th quarter worth about $115,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CAMP shares. Rodman & Renshaw began coverage on CAMP4 Therapeutics in a research report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price objective on the stock. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Zacks Research cut CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Finally, Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $8.36.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.